ABG Sundal Collier acted as Joint Global Coordinator and Joint Bookrunner in the NOK 250 million private placement in Nordic Nanovector ASA

On 19 February 2022, Nordic Nanovector announced the successful placement of 17,857,143 new shares. The private placement was completed at a subscription price of NOK 14 per share, which was determined through an accelerated book-building process, for a total transaction size of NOK 250 million.
The proceeds from the private placement are expected to ensure financing past the Company’s value inflection point targeted for H2’2022 (preliminary 3-month data readout from PARADIGME) and for at least an additional three months into 2023 to enable the Company to maximize shareholder value from the PARADIGME clinical trial.
Further, the net proceeds to the Company from the private placement will be used for (i) preparation of activities required for the regulatory filing of Betalutin® and pre-approval inspections, (ii) continue the preparatory activities for the confirmatory Phase 3 trial including production of clinical material and preparation for market launch and (iii) general corporate purposes.